Open-label, single-arm, phase II trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer
Journal of Hepatology · 2026-04 · 84 (4) · 766-775
DOI: 10.1016/j.jhep.2025.10.032 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Hepatology, 2026-04. Verfasst von Jeesun Yoon und 10 weiteren Autor:innen. Beteiligte Einrichtung: Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical …. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Biliary Tract Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Research Foundation of Korea, Seoul National University, Seoul National University College of Medicine.
Abstract (Originalsprache)
BACKGROUND & AIMS: Immune checkpoint inhibitors (ICIs) combined with cytotoxic chemotherapy are now the standard first-line treatment for advanced biliary tract cancer (BTC). With this evolving landscape, therapeutic options using ICIs after first-line failure are urgently needed. Anti-angiogenic agents may enhance anti-tumor immunity by increasing tumor antigen presentation and promoting lymphocyte infiltration and migration. We aimed to evaluate the efficacy of sitravatinib plus tislelizumab as second-line therapy for advanced BTC. METHODS: In this open-label, single-arm, phase II trial, patients were enrolled regardless of prior ICI treatment history. The primary endpoint was disease control rate. Key secondary endpoints included objective response rate, progression-free survival, overall survival, safety, and biomarker analyses (NCT04727996). RESULTS: A total of 43 patients were enrolled. The median follow-up was 10.5 months (95% CI 7.03-15.6). Nine patients had previously received ICI therapy. The disease control rate was 65.1% (95% CI 50.3-78.0), and the objective response rate was 18.6% (95% CI 9.2-32.1). Median progression-free and overall survival were 4.93 months (95% CI 3.10-8.87) and 10.3 months (95% CI 6.67-18.2), respectively. Anti-tumor activity was observed regardless of prior ICI exposure. The most common treatment-related adverse events were associated with sitravatinib and were predominantly grade 1-2. In exploratory analyses, patients with homologous recombination deficiency (HRD), detected by baseline tissue next-generation sequencing (frequency 18.5%), showed better outcomes than those without HRD. Responders displayed higher inflammatory signaling in baseline and on-treatment tumor tissue compared with non-responders. CONCLUSIONS: Sitravatinib plus tislelizumab demonstrated meaningful efficacy and an acceptable safety profile as second-line therapy for advanced BTC. HRD-based patient selection may provide a promising strategy for optimizing treatment in this setting. GOV IDENTIFIER: NCT04727996 IMPACT AND IMPLICATIONS: The results of this multi-center, open-label, phase II study suggest that immunotherapy and anti-angiogenic agent combination treatment has a promising efficacy and safety as second-line treatment for patients with advanced biliary tract cancer. Furthermore, the presence of homologous recombination deficiency detected on tumor next-generation sequencing may select patients who have benefit from this combination, which supports further research exploring immunotherapy with anti-angiogenics combination strategy in this setting. CLINICALTRIALS: gov Identifier NCT04727996.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, South Korea.
- Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.
- Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea.
- Division of Medical Oncology, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
- Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, South Korea…
Förderung
- National Research Foundation of Korea
- Seoul National University
- Seoul National University College of Medicine
- BeiGene
Zitieren
APA
Yoon, J., Lee, C. K., Kim, J. W., Kang, B., Park, S. J., Kim, J. W., Chon, H. J., Choi, H. J., Lee, M. A., Kim, T. Y., & Oh, D. Y. (2026). Open-label, single-arm, phase II trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer. Journal of Hepatology, 84(4), 766-775. https://doi.org/10.1016/j.jhep.2025.10.032
Vancouver
Yoon J, Lee CK, Kim JW, Kang B, Park SJ, Kim JW, et al. Open-label, single-arm, phase II trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer. Journal of Hepatology. 2026;84(4):766-775. doi:10.1016/j.jhep.2025.10.032
BibTeX
@article{Yoon2026,
author = {Yoon, Jeesun and Lee, Choong-Kun and Kim, Jin Won and Kang, Beodeul and Park, Se Jun and Kim, Ji-Won and Chon, Hong Jae and Choi, Hye Jin and Lee, Myung Ah and Kim, Tae-Yong and Oh, Do-Youn},
title = {Open-label, single-arm, phase II trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer},
journal = {Journal of Hepatology},
year = {2026},
volume = {84},
number = {4},
pages = {766--775},
doi = {10.1016/j.jhep.2025.10.032}
}
EUVIMED